Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP5166)
Name
Acorus calamus
Species Origin Acorus calamus ...     Click to Show/Hide
Acorus calamus
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Acorales
Family: Acoraceae
Genus: Acorus
Species: Acorus calamus
Disease Lung cancer [ICD-11: 2C25] Investigative [1]
Herb ID
HERB000164
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Azoles + Amphotericin B     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Candida species Microorganism model Candida species
                    Experimental
                    Result(s)
The combined effects of asarones and drugs principally recorded substantial synergistic activity (fractional inhibitory concentration index (FICI) <0.5).
References
Reference 1 Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice. Bull Exp Biol Med. 2017 Nov;164(1):102-105.
Reference 2 Asarones from Acorus calamus in combination with azoles and amphotericin B: a novel synergistic combination to compete against human pathogenic Candida species in vitro. Appl Biochem Biotechnol. 2015 Apr;175(8):3683-95.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China